Stifel Maintains Price Target on Iovance Shares After Promising Trial Data
Friday, 31 May 2024, 16:33
Stifel Upholds Price Target on Iovance Shares
Stifel, a notable financial institution, has decided to maintain its price target on Iovance Biotherapeutics shares following the unveiling of positive trial results. This move signifies Stifel's ongoing support and belief in the company's future prospects.
Reasoning Behind the Decision
Stifel's decision to keep the price target intact is based on the promising outcomes of recent trials conducted by Iovance Biotherapeutics, showcasing its potential for growth and success.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.